POLSINELLI

Stacie L. Ropka, Ph.D.

SENIOR PARTNER

Washington, D.C. | 202.626.8307
sropka@polsinelli.com

With more than 20 years of experience practicing law, Stacie Ropka focuses on Hatch-Waxman litigation and assessing litigation strategies in the Biotech space. In addition, Stacie is heavily involved in due diligence and client counseling with an emphasis on life sciences, reconstructive biomaterials, biologics and biologic-based pharmaceuticals.

In addition to a J.D., Stacie holds a Ph.D. in Microbiology and Immunology. Prior to graduating from law school, she held a faculty position at SUNY Upstate Medical University. Stacie also spent many years as a research scientist in the fields of neurology (particularly neuromuscular disease), virology and immunology, both at Northwestern University and SUNY Upstate Medical University. She has presented original research at numerous scientific conferences and has published in peer-reviewed journals.

Education

- Syracuse University College of Law (J.D., *magna cum laude, Order of the Coif*, 2005)
- SUNY Health Science Center (Ph.D., *with distinction*, 1999)
- DePaul University (M.B.A., 1986)
    - Marketing
- DePaul University (M.S., 1984)
    - Endocrinology
- DePaul University (B.S., 1982)
    - Biology

Bar Admissions

- New Jersey
- Connecticut
- District of Columbia

Court Admissions

- U.S. District Court, District of New Jersey
- U.S. District Court, District of Connecticut

Capabilities

- Hatch-Waxman & Biologics
- Intellectual Property
- Life Sciences
- Intellectual Property Litigation

Memberships

- The Center for Biosimilars' Board of Advisors

Recognition

- Selected for inclusion in *Best Lawyers in America*®, 2024-2026
- Named to "Remarkable Women in Business" by Hartford Business Journal
- Named to "Women Worth Watching in STEM 2017" by *Profiles in Diversity Journal*
- Named to "Women Worth Watching 2015" by *Profiles in Diversity Journal*

Matters

- Served on the pre-trial and trail teams for numerous Hatch-Waxman matters
- Conducted IP due diligence for a number of biosimilar matters
- Conducted IP due diligence for a number of reconstructive biomaterial matters
- Conducted IP due diligence for a number of genetically modified cell matters